BASEL, Switzerland, July 21, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS) delivers strong first-half performance and continues to gain market share.
- Group sales up 20%; Pharmaceuticals climbs 18%, outpacing the market; Sandoz (Generics) jumps 87%
- Group operating income expands 16% despite significant investments in R&D
- Attractive in-licensing opportunities captured: Idenix, Regeneron and Enablex deals successfully completed
- Free cash flow up 155%; net income increases by 1% and earnings per share by 4%
Commenting on Novartis' first-half and second-quarter results published today, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: "I am pleased with our strong performance as our consistent strategy continues to deliver double-digit sales growth and market share gains. For the remainder of the year, we forecast continued strong sales growth, with earnings supporting our strategy to bolster research and development and bring innovative medicines to patients."
Please see full press release under the following link: http://reports.huginonline.com/911326/120464.pdf